The domestic drug price system is gradually clear, and the internationalization of innovative drugs will enter a critical period

The National Medical Insurance Administration has adjusted the list of medical insurance drugs for three consecutive years since 2018, and organized a total of six batches of national drug centralized procurement
.
From the current point of view, centralized procurement and national talks have extensively covered generic drugs and new drug varieties.
After the reshaping of drug prices, more and more common diseases, major diseases, and rare disease drugs are included in medical insurance, allowing the majority of patients Benefit
.
It is worth noting that with the steady advancement of medical reform and the continuous expansion of centralized procurement, the innovation and transformation of domestic pharmaceutical companies have also begun to accelerate
.
Data show that the R&D investment of listed biomedical companies is continuously expanding
.
In 2020, the R&D expenditure of listed biomedical companies in China will be 11.
534 billion yuan, a year-on-year increase of 37.
10%
.
By the first half of 2021, the R&D expenditures of listed biomedical companies in China have reached 6.
978 billion yuan, and the R&D expenditures for the whole year are expected to continue to grow.
With high R&D investment, the transformation of research results of pharmaceutical companies is still accelerating
.
On the whole, the innovative drug industry has ushered in rapid development, and the number of new drugs approved and the proportion of clinical trial applications are reaching new highs year by year
.
In this context, the industry predicts that there will be two major trends when domestic pharmaceutical companies develop innovative drugs in the future
.
First of all, more local innovative drug projects will be favored by international pharmaceutical companies
.
It is understood that with the advancement of medical reform and drug reform in recent years, the license-in and license-out of pharmaceutical companies have actually become very popular, and they have gradually become a trend
.
According to statistics, in 2020, the number of Chinese medicines going overseas has reached 23, and as of August 2021, there have been 13 overseas authorized projects
.
The license-outs of companies such as Baiji, Cinda, Jacos, and Rongchang Bio have all brought tens of millions of dollars and hundreds of millions of dollars in milestone benefits
.
Recently, Shanghai Pharmaceuticals has just announced an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China.

.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it also marks a milestone in the company's significant progress in R&D and innovation capabilities
.
The analysis believes that with the continuous improvement of the innovation strength of domestic enterprises, the number of license-out projects of Chinese pharmaceutical companies will increase in the future, and even exceed the license-in
.
But whether it is License-in or License-out, international cooperation in medicine will become the new normal
.
Secondly, project cooperation between local companies will gradually increase
.
It is reported that in recent years, as the normalization of a series of medical insurance control policies such as centralized procurement has accelerated, the cooperation between local pharmaceutical companies and innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies has been increasing
.
For example, on November 22, Connoa announced that it will cooperate with CSPC on the exclusive use of the innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
Authorized development and commercialization formally signed an agreement
.
In general, in the context of a series of medical reform policies, accelerated reshuffle of the pharmaceutical industry, and accelerated innovation and transformation of pharmaceutical companies, there are more and more cases of cooperation between domestic pharmaceutical companies and between Chinese and foreign pharmaceutical companies
.
It is expected that in the future, through cooperation, companies will be able to achieve greater mutual complementarity, and at the same time, they can share risks, better promote research and development, accelerate the commercialization process, and better benefit more and more patients
.
However, it should be noted that at the same time, the industry has also proposed that domestic pharmaceutical companies should continue to accelerate the internationalization of domestic innovative drugs.
After all, only with international competitiveness can they have domestic and foreign market competitiveness
.